More than 130 suppliers
ISO certified
In-house tech support
we Connect you
Bio-Connect
ProductsBack/PP1 [172889-26-8]
Chemical Structure
Chemical Structure
Chemical Structure

PP1 [172889-26-8]

Research Use Only
AG-CR1-3562
AdipoGen Life Sciences
CAS Number172889-26-8
DownloadDatasheet
DownloadMSDS
Product group Chemicals
Estimated Purity>98%
Molecular Weight281.4
Price on request
Packing Size
Large volume orders?
Order with a bulk request
More than 130 suppliers
ISO certified
In-house tech support

Overview

  • Supplier
    AdipoGen Life Sciences
  • Product Name
    PP1 [172889-26-8]
  • Delivery Days Customer
    10
  • CAS Number
    172889-26-8
  • Certification
    Research Use Only
  • Estimated Purity
    >98%
  • Hazard Information
    Non-hazardous,Warning
  • Molecular Formula
    C16H19N5
  • Molecular Weight
    281.4
  • Scientific Description
    Chemical. CAS: 172889-26-8. Formula: C16H19N5. MW: 281.4. Highly potent and selective Scr family tyrosine kinase inhibitor. Shows anti-Ras cancer potential by blocking Ras-induced activation of PAK1. Antitumor compound. RIP2 inhibitor. Blocks TGF-beta-mediated cellular responses. - Highly potent and selective Scr family tyrosine kinase inhibitor [1, 2, 6, 9]. Shows anti-Ras cancer potential by blocking Ras-induced activation of PAK1 [4]. Antitumor compound [3, 4, 5, 7]. RIP2 inhibitor [9]. Blocks TGF-beta-mediated cellular responses [8, 10].
  • SMILES
    CC1=CC=C(C=C1)C1=NN(C2=C1C(N)=NC=N2)C(C)(C)C
  • Storage Instruction
    2°C to 8°C,-20°C
  • UNSPSC
    12352200

References

  • Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation: J.H. Hanke, et al.; J. Biol. Chem. 271, 695 (1996)
  • Src family-selective tyrosine kinase inhibitor, PP1, inhibits both Fc epsilonRI- and Thy-1-mediated activation of rat basophilic leukemia cells: M. Amoui, et al.; Eur. J. Immunol. 27, 1881 (1997)
  • Lck associates with and is activated by Kit in a small cell lung cancer cell line: inhibition of SCF-mediated growth by the Src family kinase inhibitor PP1: G.W. Krystal, et al.; Cancer Res. 58, 4660 (1998)
  • An anti-Ras cancer potential of PP1, an inhibitor specific for Src family kinases: in vitro and in vivo studies: H. He, et al.; Cancer J. 6, 243 (2000)
  • The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes: F. Carlomagno, et al.; Cancer Res. 62, 1077 (2002)
  • The specificities of protein kinase inhibitors: an update: J. Bain, et al.; Biochem. J. 371, 199 (2003)
  • The Src-selective kinase inhibitor PP1 also inhibits Kit and Bcr-Abl tyrosine kinases: L. Tatton, et al.; J. Biol. Chem. 278, 4847 (2003)
  • Src activation is not necessary for transforming growth factor (TGF)-beta-mediated epithelial to mesenchymal transitions (EMT) in mammary epithelial cells. PP1 directly inhibits TGF-beta receptors I and II: M. Maeda, et al.; J. Biol. Chem. 281, 59 (2006)
  • The selectivity of protein kinase inhibitors: a further update: J. Bain, et al.; Biochem. J. 408, 297 (2007)
  • The Src family kinase inhibitors PP2 and PP1 block TGF-beta1-mediated cellular responses by direct and differential inhibition of type I and type II TGF-beta receptors: H. Ungefroren, et al.; Curr. Cancer Drug Targets 11, 524 (2011)